An immunogenic peptide for use in the prevention of parvovirus infections having a contiguous sequence of 6 to 25 amino acids. The peptide is produced from autonomous parvoviruses so as to be capable of inducing neutralizing antibodies against such viruses. These peptides correspond to antigenic sites located in the first 25 amino acids of the amino terminal end of the VP2 proteins of parvoviruses. When these peptides are coupled to carrier proteins or to other immunogenic complexes, they can be used in the formulation of vaccines appropriate to protect dogs, cats, pigs and minks against the infections caused by the parvoviruses.